Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TRIAZOLAM

2 general benefit · 2 not a benefit

Other products in the same Health Canada class (N05C, N05CD) — coverage varies; not interchangeable

  • Flurazepam (Dalmane): general benefit, Not a benefit
  • Nitrazepam (Mogadon): general benefit
  • Temazepam (Restoril): general benefit
  • Midazolam (Versed): limited Use 495, 496, Not a benefit
  • Eszopiclone (Lunesta): not a benefit
  • Zolpidem (Sublinox): not a benefit

1 more in the class list below

Triazolam · DIN 00808571 · 0.25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Triazolam · DIN 00808571 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2014-06-27 · brand TRIAZOLAM · ATC N05CD05 TRIAZOLAM · form Tablet · route Oral · ingredients TRIAZOLAM 0.25 MG · company Aa pharma inc · schedule Targeted substances (cdsa iv)
Check this DIN again · Health Canada product record

Triazolam: Formulary list price $0.2551/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2551 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9575 · Verify on the e-Formulary ↗ (DIN 00808571)

Source record
DIN 00808571: Triazolam Raw flags: sec3=Y Item: 282400056; group id 529; item number 1432; lccId None; manufacturer id AAP Source form: Tab; strength: 0.25mg Recorded listing: General benefit Source prices (unrounded): $0.2551; ministry $0.2551 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00808571 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9575
Interchangeable products
Halcion · DIN 00443158 · not recorded
Shortage status: resolved shortage (ended 2019-10-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00808571
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Triazolam · DIN 00808563 · 0.125mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2014-11-07 — choose a marketed DIN from the same-category list.Discontinued 2014-11-07 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2014-11-07 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2014-11-07 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Triazolam · DIN 00808563 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2014-11-07 · brand TRIAZOLAM · ATC N05CD05 TRIAZOLAM · form Tablet · route Oral · ingredients TRIAZOLAM 0.125 MG · company Aa pharma inc · schedule Targeted substances (cdsa iv)
Check this DIN again · Health Canada product record

Triazolam: Formulary list price $0.1496/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1496 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9574 · Verify on the e-Formulary ↗ (DIN 00808563)

Source record
DIN 00808563: Triazolam Raw flags: sec3=Y Item: 282400057; group id 529; item number 1431; lccId None; manufacturer id AAP Source form: Tab; strength: 0.125mg Recorded listing: General benefit Source prices (unrounded): $0.1496; ministry $0.1496 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00808563 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9574
Interchangeable products
Halcion · DIN 00512559 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00808563
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2014-11-07 — choose a marketed DIN from the same-category list.

Halcion · DIN 00512559 · 0.125mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-08-02 — choose a marketed DIN from the same-category list.Discontinued 2006-08-02 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-08-02 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2006-08-02 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Halcion · DIN 00512559 Manufacturer: The Upjohn Company of Canada; listing date 1996-10-01 Health Canada: Cancelled post market since 2006-08-02 · brand HALCION · ATC N05CD05 TRIAZOLAM · form Tablet · route Oral · ingredients TRIAZOLAM 0.125 MG · company Pfizer canada ulc · schedule Targeted substances (cdsa iv)
Check this DIN again · Health Canada product record

Halcion: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4065 · Verify on the e-Formulary ↗ (DIN 00512559)

Source record
DIN 00512559: Halcion Raw flags: notABenefit=Y, sec3=Y Item: 282400057; group id 529; item number 1431; lccId None; manufacturer id UPJ Source form: Tab; strength: 0.125mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00512559 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4065
Interchangeable products
Triazolam · DIN 00808563 · $0.1496
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00512559
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2006-08-02 — choose a marketed DIN from the same-category list.

Halcion · DIN 00443158 · 0.25mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-05-29 — choose a marketed DIN from the same-category list.Discontinued 2007-05-29 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-05-29 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2007-05-29 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Halcion · DIN 00443158 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2007-05-29 · brand HALCION · ATC N05CD05 TRIAZOLAM · form Tablet · route Oral · ingredients TRIAZOLAM 0.25 MG · company Pfizer canada ulc · schedule Targeted substances (cdsa iv)
Check this DIN again · Health Canada product record

Halcion: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3113 · Verify on the e-Formulary ↗ (DIN 00443158)

Source record
DIN 00443158: Halcion Raw flags: notABenefit=Y, sec3=Y Item: 282400056; group id 529; item number 1432; lccId None; manufacturer id PFI Source form: Tab; strength: 0.25mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00443158 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3113
Interchangeable products
Triazolam · DIN 00808571 · $0.2551
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00443158
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2007-05-29 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:24 Sedatives and Hypnotics) and how they are covered

Matched class: 28:24 Sedatives and Hypnotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: NITRAZEPAM, PHENOBARBITAL, TEMAZEPAM Some products covered without a code (check the product listing): BUSPIRONE HYDROCHLORIDE, FLURAZEPAM, METHOTRIMEPRAZINE 28:24 Sedatives and Hypnotics

FLURAZEPAM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 15mg, 30mg · Cap

NITRAZEPAM

· 2 products · General benefit · strengths: 5mg, 10mg · Tab

TEMAZEPAM

· 2 products · General benefit · strengths: 15mg, 30mg · Cap

MIDAZOLAM

· 3 products · Listed, not a benefit (1), Limited Use, codes 495, 496 (2) · strengths: 5mg/mL · Inj Sol (with Preservative)

ESZOPICLONE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2mg, 3mg · Tab

ZOLPIDEM TARTRATE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · SL Tab

ZOPICLONE

· 40 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 3.75mg, 5mg, 7.5mg · Tab

BUSPIRONE HYDROCHLORIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 10mg · Tab

METHOTRIMEPRAZINE

· 9 products · General benefit (5), Listed, not a benefit (4) · strengths: 25mg/mL, 2mg, 5mg, 25mg, 50mg · Inj Sol-1mL Pk, Tab

PHENOBARBITAL

· 5 products · General benefit · strengths: 5mg/mL, 15mg, 30mg, 60mg, 100mg · Oral Elixir, Tab

LORAZEPAM

· 9 products · Listed, not a benefit (1), Limited Use, codes 481 (2), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 4mg/mL, 0.5mg, 1mg, 2mg · Inj Sol (with preservative), SL Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:24
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS TRIAZOLAM (Triazolam Tablets USP) is indicated for  the symptomatic relief of transient and short-term insomnia in patients who have difficulty falling asleep. Triazolam is not recommended for early morning awakenings. The use of hypnotics should be restricted for insomnia where disturbed sleep results in impaired daytime functioning. 1.1 Pediatrics Pediatrics (<18 years): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of TRIAZOLAM in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. See 7 WARNINGS AND PRECAUTIONS. 1.2 Geriatrics Long-term use of TRIAZOLAM should be avoided in elderly patients. Enhanced monitoring is recommended. See 7 WARNINGS AND PRECAUTIONS, Falls and fractures; 4.1 Dosing considerations. https://pdf.hres.ca/dpd_pm/00064008.PDF PM date: DEC 31, 1989 Source product: TRIAZOLAM; DIN 00808571; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Halcion: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026